Equities research analysts forecast that Sierra Oncology, Inc. (NASDAQ:SRRA – Get Rating) will announce earnings of ($0.95) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Sierra Oncology’s earnings, with the highest EPS estimate coming in at ($0.88) and the lowest estimate coming in at ($1.02). Sierra […]
Sierra Oncology (NASDAQ:SRRA – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. The brokerage currently has a $61.00 target price on the biotechnology company’s stock. Zacks Investment Research‘s price objective indicates a potential upside […]
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.
12.05.2022 - Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the program for the 2022 Annual Meeting of the . Seite 1